

Accelerating Access Initiative (AAI) - Fact Sheet

Estimated number of people living with HIV in developing countries receiving antiretroviral (ARV) treatment with medicines provided by the AAI as of March 2005


- Established in 2000, the Accelerating Access Initiative (AAI) involves seven research-based pharmaceutical companies; Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Roche, and Merck & Co., Inc, and five United Nations partners; UNAIDS, the World Health Organization, World Bank, UNICEF, and the United Nations Population Fund (UNFPA)
- The AAI combines pharmaceutical industry research knowledge with that of its partners to establish practical, long-term solutions that help to improve access to HIV healthcare in resource-poor countries
- The AAI companies remain committed to dialogue with all external organisations sharing similar goals to help people living with HIV/AIDS in the poorest countries. AAI members are actively engaged with many groups focused towards making meaningful and practical differences on the ground

Data on patients receiving treatment with ARV medicines provided by the AAI companies – Quarter 1 , 2005

- In March 2005, a total of 427,000 people living with HIV/AIDS in developing countries were receiving treatment with ARV medicines provided by the AAI companies
- The total number of patients receiving treatment from the AAI companies increased by 47% on the previous year, with 130,000 people initiated on treatment during 2004
- In Africa alone, 216,000 patients are being treated with medicines supplied by the AAI companies. With an increase in excess of 121% on the previous year, there has been a 23-fold increase in Africa since the establishment of the AAI in May 2000
- The estimated number of people on treatment is based on actual quarterly drug supply data from the seven companies. The drug unit data were converted into patient-equivalent numbers by quarter, based on dosage and indications.¹ The data are therefore

collected precisely and consistently as they represent units supplied and actual sales, and the analysis is underpinned by reliable data²

- The summary data are included below, together with a graph of the growth in estimated number of patients treated since the AAI began³



Actual results as reported		Total number of patients																			
Regions	Q1-00	Q2-00	Q3-00	Q4-00	Q1-01	Q2-01	Q3-01	Q4-01	Q1-02	Q2-02	Q3-02	Q4-02	Q1-03	Q2-03	Q3-03	Q4-03	Q1-04	Q2-04	Q3-04	Q4-04	Q1-05
Africa	9,393	9,737	9,574	12,092	21,203	17,373	29,047	36,102	39,510	55,202	44,155	40,662	45,547	75,145	103,499	152,828	97,991	110,729	157,633	193,370	216,103
Central & Latin & South America	26,624	60,156	95,527	71,440	55,757	79,207	87,178	90,811	72,838	85,944	74,235	74,954	61,379	111,843	75,522	83,427	145,894	148,852	126,906	137,890	157,537
Middle East & Asia	12,222	11,248	9,551	10,016	11,701	13,372	12,201	15,211	15,118	20,952	18,917	21,252	15,957	11,994	20,151	23,301	35,783	72,666	37,347	38,913	42,528
Eastern Europe	2,512	3,256	1,422	3,927	3,902	5,379	5,824	6,787	10,025	18,751	8,920	11,000	5,822	8,934	5,607	9,193	11,045	12,234	11,188	12,237	11,173
Total	50,750	84,396	116,074	97,473	92,583	115,331	134,249	148,971	137,491	160,848	146,226	147,867	128,705	207,915	204,779	268,748	290,712	344,481	333,074	382,410	427,341

4 quarters moving average results		Total number of patients																			
Regions	Q1-00	Q2-00	Q3-00	Q4-00	Q1-01	Q2-01	Q3-01	Q4-01	Q1-02	Q2-02	Q3-02	Q4-02	Q1-03	Q2-03	Q3-03	Q4-03	Q1-04	Q2-04	Q3-04	Q4-04	Q1-05
Africa	10,199	13,152	15,060	19,929	25,931	30,508	39,965	43,742	44,862	46,391	51,377	66,213	94,255	107,366	116,262	129,795	139,931	169,459			
Central & Latin & South America	63,437	70,720	75,483	73,395	78,238	82,508	79,193	75,957	71,993	69,126	80,603	80,925	83,043	104,172	113,424	126,270	139,895	142,796			
Middle East & Asia	10,759	10,629	11,160	11,822	13,136	13,960	15,385	17,584	19,059	19,269	17,030	17,338	17,851	22,807	37,975	42,274	46,177	47,863			
Eastern Europe	2,779	3,136	3,657	4,759	5,473	7,004	10,347	11,121	12,174	11,123	8,689	7,840	7,389	8,694	9,519	10,915	11,676	11,708			
Total	87,173	97,627	105,360	109,904	122,779	134,011	145,390	148,384	148,108	145,912	157,678	172,317	202,537	243,039	277,180	309,254	337,689	371,626			

###

¹ The estimated patient numbers are a conservative estimate of the number of people actually treated with antiretrovirals in developing countries, since they do not take into account such factors as patient adherence to therapy, the number of children treated, use of other drugs, and drug wastage.

² The calculated number of patients represents only an estimate of the number of patients treated by ARVs supplied by the AAI companies. The figures do not represent an estimate of the *total* number of patients treated in these countries, as they do not take into account the patients treated with antiretrovirals supplied by other companies. Thus, due to the factors noted above, the actual number of patients treated is likely to be higher than the reported figure of 427,341

³ This figure shows both the actual numbers as reported (dotted lines) and 4-quarter moving averages (solid lines). The moving averages provide a clearer view of the long-term trends in patient numbers, since they smooth the quarter-by-quarter variations that can occur due to tenders or other unusual buying patterns.